179 related articles for article (PubMed ID: 9230243)
1. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment.
De Flora S; Grassi C; Carati L
Eur Respir J; 1997 Jul; 10(7):1535-41. PubMed ID: 9230243
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
Grandjean EM; Berthet P; Ruffmann R; Leuenberger P
Clin Ther; 2000 Feb; 22(2):209-21. PubMed ID: 10743980
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
[TBL] [Abstract][Full Text] [Related]
4. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Hayden FG; Atmar RL; Schilling M; Johnson C; Poretz D; Paar D; Huson L; Ward P; Mills RG
N Engl J Med; 1999 Oct; 341(18):1336-43. PubMed ID: 10536125
[TBL] [Abstract][Full Text] [Related]
5. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease.
Kasielski M; Nowak D
Respir Med; 2001 Jun; 95(6):448-56. PubMed ID: 11421501
[TBL] [Abstract][Full Text] [Related]
6. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population.
Ambrozaitis A; Gravenstein S; van Essen GA; Rubinstein E; Balciuniene L; Stikleryte A; Crawford C; Elliott M; Shult P
J Am Med Dir Assoc; 2005; 6(6):367-74. PubMed ID: 16286057
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine replenishes glutathione in HIV infection.
De Rosa SC; Zaretsky MD; Dubs JG; Roederer M; Anderson M; Green A; Mitra D; Watanabe N; Nakamura H; Tjioe I; Deresinski SC; Moore WA; Ela SW; Parks D; Herzenberg LA; Herzenberg LA
Eur J Clin Invest; 2000 Oct; 30(10):915-29. PubMed ID: 11029607
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.
Geiler J; Michaelis M; Naczk P; Leutz A; Langer K; Doerr HW; Cinatl J
Biochem Pharmacol; 2010 Feb; 79(3):413-20. PubMed ID: 19732754
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
[TBL] [Abstract][Full Text] [Related]
10. The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial.
Skvarc DR; Dean OM; Byrne LK; Gray LJ; Ives K; Lane SE; Lewis M; Osborne C; Page R; Stupart D; Turner A; Berk M; Marriott AJ
Trials; 2016 Aug; 17():395. PubMed ID: 27502769
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Treanor JJ; Hayden FG; Vrooman PS; Barbarash R; Bettis R; Riff D; Singh S; Kinnersley N; Ward P; Mills RG
JAMA; 2000 Feb; 283(8):1016-24. PubMed ID: 10697061
[TBL] [Abstract][Full Text] [Related]
12. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
13. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
[TBL] [Abstract][Full Text] [Related]
14. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.
Moist L; Sontrop JM; Gallo K; Mainra R; Cutler M; Freeman D; House AA
Am J Kidney Dis; 2010 Oct; 56(4):643-50. PubMed ID: 20541301
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection.
Garozzo A; Tempera G; Ungheri D; Timpanaro R; Castro A
Int J Immunopathol Pharmacol; 2007; 20(2):349-54. PubMed ID: 17624247
[TBL] [Abstract][Full Text] [Related]
17. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
[TBL] [Abstract][Full Text] [Related]
18. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Rasmussen JB; Glennow C
Eur Respir J; 1988 Apr; 1(4):351-5. PubMed ID: 3294038
[TBL] [Abstract][Full Text] [Related]
19. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
Correa MJ; Mariz HA; Andrade LE; Kayser C
Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
[TBL] [Abstract][Full Text] [Related]
20. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
